# Autologous Platelet-rich Plasma (PRP) and Thrombin Coagulum for the Topical Treatment of Rectal Mucosal Ulcers

> **NCT05912712** · PHASE1 · UNKNOWN · sponsor: **Xijing Hospital of Digestive Diseases** · enrollment: 60 (estimated)

## Conditions studied

- Ulcerative Colitis Chronic Moderate
- Ulcerative Colitis Chronic Severe
- Rectal Ulcer

## Interventions

- **OTHER:** Autologous Platelet-rich Plasma (PRP) and Thrombin Coagulum Treatment
- **OTHER:** Autologous Platelet-poor Plasma (PPP) and Thrombin Coagulum Treatment
- **DRUG:** Mesalazine Suppository Treatment
- **BIOLOGICAL:** Infliximab Treatment

## Key facts

- **NCT ID:** NCT05912712
- **Lead sponsor:** Xijing Hospital of Digestive Diseases
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-01
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05912712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05912712, "Autologous Platelet-rich Plasma (PRP) and Thrombin Coagulum for the Topical Treatment of Rectal Mucosal Ulcers". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05912712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*